Literature DB >> 8572212

Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition.

W D Chey1, A Beydoun, D J Roberts, W L Hasler, C Owyang.   

Abstract

Octreotide reduces perception of rectal distension in normal volunteers and irritable bowel patients. To localize octreotide's site of action, perceptual and evoked potential responses to rectal electrical stimulation were tested in seven normal volunteers after double-blind octreotide (100 micrograms 2) or placebo. After octreotide, the currents needed to elicit threshold perception of square-wave impulses delivered to the rectum were 29% higher than after placebo. When electrical stimulation was delivered at constant currents 50% above threshold, rectal perception scores were significantly reduced after octreotide compared with placebo. Rectal electrical stimulation led to characteristic and reproducible cerebral evoked potentials. Octreotide had no effect on latencies, but reduced peak-to-peak amplitudes by 35% compared with placebo. Rectal electrical stimulation also led to characteristic and reproducible spinal evoked potentials. Octreotide had no effect on spinal latencies, but reduced peak-to-peak amplitudes by 51%. In conclusion, octreotide reduces perception of rectal electrical stimulation, which is associated with inhibition of cerebral and spinal evoked potential amplitude, indicating effects on spinal afferent pathways.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8572212     DOI: 10.1152/ajpgi.1995.269.6.G821

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Some of the challenges in drug development for irritable bowel syndrome.

Authors:  E A Mayer
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.

Authors:  M Camilleri
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

3.  Cortical and spinal evoked potential response to electrical stimulation in human rectum.

Authors:  Brian Garvin; Lisa Lovely; Alex Tsodikov; Danielle Minecan; Shaungson Hong; John W Wiley
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

4.  Effects of octreotide on responses to colorectal distension in the rat.

Authors:  X Su; M B Burton; G F Gebhart
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 5.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

Review 6.  Pharmacotherapy: non-serotonergic mechanisms.

Authors:  R Spiller
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 7.  Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome.

Authors:  M Delvaux
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 8.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

9.  Inhibition of visceral nociceptors.

Authors:  David E Reed; L Ashley Blackshaw
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.